SCHEMBL621796

SCHEMBL621796

Cc1ccc(-c2cccc(-c3ccccc3)c2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 2/20 0.53
CYP1A2 P05177 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP3A4 P08684 1/20 0.43
SMO Q99835 1/20 0.42
KMO O15229 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ESR1 P03372 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
AHR P35869 1/20 0.41
ALDH1A1 P00352 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
MAOA P21397 1/20 0.40
HSD17B1 P14061 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1755256 0.96 ESR2 (0.57) ESR2CYP1A2KDM4ECYP3A4KMO
SCHEMBL31614097 0.96 ESR2 (0.57) ESR2CYP1A2KDM4ECYP3A4KMO
Cyanide SCHEMBL30277419 0.90 ESR2 (0.52) ESR2CYP1A2KDM4ECYP3A4KMO
SCHEMBL12259927 0.84 CYP3A4 (0.56) KDM4ECYP3A4KMOMEN1KMT2A
SCHEMBL13494487 0.80 CYP3A4 (0.48) KDM4ECYP3A4KMONPC1TSHR
SCHEMBL13906332 0.80 AHR (0.56) CYP1A2KDM4ECYP3A4KMONPC1
SCHEMBL15116986 0.79 KDM4E (0.41) ESR2CYP1A2KDM4ECYP3A4KMO
SCHEMBL308031 0.78 ESR2 (0.52) ESR2CYP1A2KDM4ECYP3A4MEN1
SCHEMBL23296152 0.78 RXRA (0.60) KDM4EKMOAKR1C2AKR1C1
SCHEMBL24245457 0.78 CYP3A4 (0.50) ESR2KDM4ECYP3A4KMOMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2603479-A2 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION E.I. Du Pont De Nemours And Company (US) 2013-06-19 EP disclosed
US-20120187383-A1 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION E.I. DU PONT DE NEMOURS AND COMPANY (US) 2012-07-26 US disclosed
WO-2012021315-A2 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-02-16 WO disclosed
CN-101948463-A Method for synthesizing substituted pyrrole by cycloaddition reaction of 1, 3-diyne and primary amine UNIV TSINGHUA 2011-01-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120187383-A1 ELECTROACTIVE COMPOUND AND COMPOSITION AND ELECTRONIC DEVICE MADE WITH THE COMPOSITION CCNL2, ESR1, ESR2 ESR2 3/4885CYP1A2 475/4885KDM4E 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.